세계의 심방세동 시장 : 제품 유형, 치료, 기술, 최종 사용자, 지역별 분석, 예측(-2032년)

According to Stratistics MRC, the Global Atrial Fibrillation Market is accounted for $17.6 billion in 2025 and is expected to reach $27.3 billion by 2032 growing at a CAGR of 6.5% during the forecast period. Atrial fibrillation is a heart rhythm disorder characterized by rapid and irregular beating of the atria, the upper chambers of the heart. It occurs when electrical signals in the atria become chaotic, disrupting the normal rhythm. This leads to poor blood circulation and increases the risk of stroke, heart failure, and other heart-related complications. Common symptoms include palpitations, fatigue, chest discomfort, and shortness of breath. Early diagnosis and management through medication, lifestyle changes, or surgical intervention are essential for effective treatment.

According to an article published in the National Center for Biotechnology Information in 2021, the prevalence of atrial fibrillation is estimated to be around 37.5 million across the globe and is projected to increase by more than 60.0% by the year 2050.

Market Dynamics:

Driver:

Increasing global prevalence of cardiovascular disorders

The rising incidence of atrial fibrillation (AFib) is linked to aging populations and lifestyle-related risk factors. Obesity, hypertension, and diabetes significantly contribute to the growing burden of cardiovascular diseases. Increased awareness of AFib symptoms prompts early diagnosis and treatment. Sedentary lifestyles and stress-related conditions further elevate the risk of heart disorders. Advancements in diagnostic tools enable better detection of AFib cases. The global demand for effective AFib treatments continues to rise.

Restraint:

Risks and complications associated with AFib treatments

AFib treatments, such as catheter ablation, carry risks of bleeding and infection. Anticoagulant medications increase the likelihood of adverse effects like excessive bleeding. High costs of advanced treatments limit accessibility for many patients. The complexity of procedures requires highly skilled professionals, which can be scarce. Patient non-compliance with long-term medication regimens poses additional challenges. These factors collectively hinder the widespread adoption of AFib therapies.

Opportunity:

Development of minimally invasive treatment options

Minimally invasive procedures like catheter ablation are gaining traction for their reduced recovery times. Innovations in ablation technologies improve precision and patient outcomes. Growing investment in research supports the development of safer treatment methods. Wearable devices for real-time heart monitoring enhance early intervention strategies. Collaborations between medical device companies and healthcare providers drive innovation. These advancements create significant growth opportunities in the AFib market.

Threat:

Intense competition among medical device manufacturers

The AFib treatment market faces fierce competition among leading medical device companies. Rapid technological advancements pressure manufacturers to innovate continuously. Smaller players struggle to compete with established brands offering advanced solutions. Price wars and cost-cutting strategies impact profit margins. Regulatory hurdles for new device approvals slow market entry. Intense competition may lead to market saturation, limiting growth for new entrants.

Covid-19 Impact:

The COVID-19 pandemic disrupted elective AFib procedures due to hospital resource constraints. Telemedicine adoption surged, enabling remote monitoring of AFib patients. Supply chain issues affected the availability of critical medical devices. The pandemic highlighted the importance of early AFib detection in high-risk patients. Post-COVID, increased healthcare spending has accelerated market recovery. Growing awareness of heart health continues to drive demand for AFib treatments.

The paroxysmal atrial fibrillation segment is expected to be the largest during the forecast period

The paroxysmal atrial fibrillation segment is expected to account for the largest market share during the forecast period, due to its high prevalence among diagnosed cases. Its intermittent nature drives demand for early diagnostic and treatment solutions. Advances in wearable monitoring devices aid in the timely detection of paroxysmal AFib. Patient preference for minimally invasive treatments boosts segment growth. Increased healthcare access supports early intervention for paroxysmal cases. The segment benefits from ongoing research into targeted therapies.

The drug therapy segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the drug therapy segment is predicted to witness the highest growth rate, due to its affordability and widespread availability. Anticoagulants and antiarrhythmic drugs remain critical for managing AFib symptoms. Ongoing research into novel drug formulations enhances treatment efficacy. Patient preference for non-invasive options drives demand for pharmaceutical solutions. Improved access to healthcare in emerging markets supports segment growth. Innovations in personalized medicine further accelerate the adoption of drug therapies.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its large aging population and rising AFib cases. Increasing healthcare expenditure in countries like China and India drives market growth. The region's expanding medical infrastructure supports advanced AFib treatments. Growing awareness of cardiovascular health boosts demand for diagnostic tools. Government initiatives to improve healthcare access enhance market potential. The presence of key medical device manufacturers strengthens the region's dominance.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, due to its advanced healthcare systems. High adoption of innovative AFib treatments like catheter ablation fuels market expansion. The region's strong focus on research and development drives technological advancements. Rising prevalence of lifestyle-related risk factors increases AFib cases. Supportive reimbursement policies enhance patient access to treatments. Strategic partnerships among key players further accelerate market growth.

Key players in the market

Some of the key players in Atrial Fibrillation Market include Abbott Laboratories, MicroPort, CardiacSense, Biosense Webster, AtriCure, LivaNova, Johnson and Johnson, ZOLL Medical, ACBIO, Medtronic, Biotronik, Philips Healthcare, Stereotaxis, Boston Scientific, and Siemens Healthineers.

Key Developments:

In May 2025, Abbott Laboratories introduced the Amplify(TM) Catheter, a next-generation ablation system with enhanced precision for treating paroxysmal atrial fibrillation.

In April 2025, Medtronic launched the PulseSelect(TM) PFA System, a novel pulsed-field ablation technology for safer and faster AFib procedures, reducing patient recovery time.

In March 2025, Boston Scientific announced the POLARx(TM) FIT Cryoablation Balloon, designed for improved adaptability in complex AFib cases, enhancing procedural outcomes.

In February 2025, Philips Healthcare debuted an AI-powered ECG monitoring platform, CardioGuard, for real-time detection of atrial fibrillation in outpatient settings.

Products Covered:

• Surgical Devices
• Non-Surgical Devices
• Pharmacological Drugs

Types Covered:

• Paroxysmal Atrial Fibrillation
• Persistent Atrial Fibrillation
• Permanent Atrial Fibrillation

Treatments Covered:

• Drug Therapy
• Cardioversion
• Catheter Ablation
• Surgical Procedures

Technologies Covered:

• Radiofrequency
• Laser
• Cryotherapy
• Other Technologies

End Users Covered:

• Hospitals
• Ambulatory Surgical Centers
• Cardiac Catheterization Laboratories
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Atrial Fibrillation Market, By Product

• 5.1 Introduction
• 5.2 Surgical Devices
• 5.3 Non-Surgical Devices
• 5.4 Pharmacological Drugs

6 Global Atrial Fibrillation Market, By Type

• 6.1 Introduction
• 6.2 Paroxysmal Atrial Fibrillation
• 6.3 Persistent Atrial Fibrillation
• 6.4 Permanent Atrial Fibrillation

7 Global Atrial Fibrillation Market, By Treatment

• 7.1 Introduction
• 7.2 Drug Therapy
• 7.3 Cardioversion
• 7.4 Catheter Ablation
• 7.5 Surgical Procedures

8 Global Atrial Fibrillation Market, By Technology

• 8.1 Introduction
• 8.2 Radiofrequency
• 8.3 Laser
• 8.4 Cryotherapy
• 8.5 Other Technologies

9 Global Atrial Fibrillation Market, By End User

• 9.1 Introduction
• 9.2 Hospitals
• 9.3 Ambulatory Surgical Centers
• 9.4 Cardiac Catheterization Laboratories
• 9.5 Other End Users

10 Global Atrial Fibrillation Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Abbott Laboratories
• 12.2 MicroPort
• 12.3 CardiacSense
• 12.4 Biosense Webster
• 12.5 AtriCure
• 12.6 LivaNova
• 12.7 Johnson and Johnson
• 12.8 ZOLL Medical
• 12.9 ACBIO
• 12.10 Medtronic
• 12.11 Biotronik
• 12.12 Philips Healthcare
• 12.13 Stereotaxis
• 12.14 Boston Scientific
• 12.15 Siemens Healthineers